
Sociobiology
Fuchsia
- Joined
- Apr 9, 2022
- Posts
- 10,792
- Reputation
- 12,070
Summary of the drug: Vorositde sold under then brand name of Xoxzogo is a drug used to treat achondrophlasia (dwarfism). This drug only works to increase height if your growth plates are open.
The drug is designed to be taken once every day at a dose 15 micrograms x every kg of body weight = daily dose. This stuff is giga expensive at $11,000 at 1 dose.
This drug is very new and considered experimental. It has be noted on sources whether or not it is effective in increasing final adult height in dwarfs (or even humans), so look into it at your own risk.
The drug is designed to be taken once every day at a dose 15 micrograms x every kg of body weight = daily dose. This stuff is giga expensive at $11,000 at 1 dose.
This drug is very new and considered experimental. It has be noted on sources whether or not it is effective in increasing final adult height in dwarfs (or even humans), so look into it at your own risk.
The safety and efficacy of vosoritide in improving growth were evaluated in a year-long, double-blind, placebo-controlled, phase III study in participants five years and older with achondroplasia who have open epiphyses.[4] In the study, 121 participants were randomly assigned to receive either vosoritide injections under the skin or a placebo.[4] Researchers measured the participants' annualized growth velocity, or rate of height growth, at the end of the year.[4] Participants who received vosoritide grew an average 1.57 centimeters taller compared to those who received a placebo.
Mechanism of action
A: Chondrocyte with constitutionally active FGFR3 that down-regulates its development via the MAPK/ERK pathway
B: Vosoritide (BMN 111) blocks this mechanism by binding to the atrial natriuretic peptide receptor B (NPR-B), which subsequently inhibits the MAPK/ERK pathway at the RAF-1 protein.[10]
Vosoritide works by binding to a receptor (target) called natriuretic peptide receptor type B (NPR-B), which reduces the activity of fibroblast growth factor receptor 3 (FGFR3).[5] FGFR3 is a receptor that normally down-regulates cartilage and bone growth when activated by one of the proteins known as acidic and basic fibroblast growth factor. It does so by inhibiting the development (cell proliferation and differentiation) of chondrocytes, the cells that produce and maintain the cartilaginous matrix which is also necessary for bone growth. Children with achondroplasia have one of several possible FGFR3 mutations resulting in constitutive (permanent) activity of this receptor, resulting in overall reduced chondrocyte activity and thus bone growth.[10]
The protein C-type natriuretic peptide (CNP), naturally found in humans, reduces the effects of over-active FGFR3. Vosoritide is a CNP analogue with the same effect but prolonged half-life,[10] allowing for once-daily administration.[11]
Vosoritide has resulted in increased growth in a clinical trial with 26 children. The ten children receiving the highest dose grew 6.1 centimetres (2.4 in) in six months, compared to 4.0 centimetres (1.6 in) in the six months before the treatment (p=0.01).
Side effects / undesirable effects / tolerability
Like all medicines, Vosoritide (Voxzogo) can cause side effects, although not everyone gets them.
Very common side effects
These may affect more than 1 in 10 people:
frequent side effects
- Vomit
- Low blood pressure (transient effects soon after the injection include feeling dizzy, tired or sick)
- Injection site reactions: redness, itching, inflammation, swelling, bruising, rash, hives, pain. Injection site reactions are usually mild and go away on their own within a few hours.
These may affect up to 1 in 10 people:
- nausea
- Feeling faint or light-headed and fainting
- dizziness
- fatigue
- High levels of alkaline phosphatase in the blood (shown in blood tests)
Last edited: